Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Treating mCRPC After Progression: The Potential Role of 225Ac-J591

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Comments
  • Overview

    Catch up on a recent study that found that the 225Ac-J591 radiopharmaceutical can be used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard treatments.

Recommended
Details
Comments
  • Overview

    Catch up on a recent study that found that the 225Ac-J591 radiopharmaceutical can be used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard treatments.

Schedule31 Oct 2024